191 related articles for article (PubMed ID: 18990200)
1. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.
Dahl CF; Allen MR; Urie PM; Hopkins PN
BMC Med; 2008 Nov; 6():34. PubMed ID: 18990200
[TBL] [Abstract][Full Text] [Related]
2. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
3. The longitudinal effects of fenfluramine-phentermine use.
Fleming RM; Boyd LB
Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
[TBL] [Abstract][Full Text] [Related]
4. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.
Maréchaux S; Jeu A; Jobic Y; Ederhy S; Donal E; Réant P; Abouth S; Arnasteen E; Boulanger J; Ennezat PV; Garban T; Szymanski C; Tribouilloy C
Arch Cardiovasc Dis; 2013; 106(6-7):349-56. PubMed ID: 23876809
[TBL] [Abstract][Full Text] [Related]
5. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
[TBL] [Abstract][Full Text] [Related]
6. Valvular heart disease with the use of fenfluramine-phentermine.
Surapaneni P; Vinales KL; Najib MQ; Chaliki HP
Tex Heart Inst J; 2011; 38(5):581-3. PubMed ID: 22163141
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
8. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
Wee CC; Phillips RS; Aurigemma G; Erban S; Kriegel G; Riley M; Douglas PS
Ann Intern Med; 1998 Dec; 129(11 Pt 1):870-4. PubMed ID: 9867728
[TBL] [Abstract][Full Text] [Related]
9. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
Burger AJ; Sherman HB; Charlamb MJ; Kim J; Asinas LA; Flickner SR; Blackburn GL
J Am Coll Cardiol; 1999 Oct; 34(4):1153-8. PubMed ID: 10520805
[TBL] [Abstract][Full Text] [Related]
10. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
Teramae CY; Connolly HM; Grogan M; Miller FA
Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
[TBL] [Abstract][Full Text] [Related]
11. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
12. Histologic changes in three explanted native cardiac valves following use of fenfluramines.
Steffee CH; Singh HK; Chitwood WR
Cardiovasc Pathol; 1999; 8(5):245-53. PubMed ID: 10533956
[TBL] [Abstract][Full Text] [Related]
13. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
Sachdev M; Miller WC; Ryan T; Jollis JG
Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
[TBL] [Abstract][Full Text] [Related]
14. Valvular heart disease associated with fenfluramine-phentermine.
Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
[TBL] [Abstract][Full Text] [Related]
15. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
[TBL] [Abstract][Full Text] [Related]
16. Operation for anorexigen-associated valvular heart disease.
Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
[TBL] [Abstract][Full Text] [Related]
17. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
[TBL] [Abstract][Full Text] [Related]
19. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation.
Mast ST; Gersing KR; Anstrom KJ; Krishnan KR; Califf RM; Jollis JG
Am J Cardiol; 2001 Apr; 87(8):989-93: A4. PubMed ID: 11305992
[TBL] [Abstract][Full Text] [Related]
20. The Doppler echocardiographic assessment of valvular regurgitation in normal children.
Ayabakan C; Ozkutlu S; Kiliç A
Turk J Pediatr; 2003; 45(2):102-7. PubMed ID: 12921295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
